Standardized statistical framework for comparison of biomarkers: Techniques from ADNI
Authors:
- Danielle J. HarveyDHDanielle J. Harvey
- For The Alzheimer'S Disease Neuroimaging InitiativeFIFor The Alzheimer'S Disease Neuroimaging Initiative
Open Access
- 13 August 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (10) , 6834-6843
Abstract
INTRODUCTION: Well‐chosen biomarkers have the potential to increase the efficiency of clinical trials and drug discovery and should show good precision as well as clinical validity.METHODS: We suggest measures that operationalize these criteria and describe a general approach that can be used for inference‐based comparisons of biomarker performance. The methods are applied to measures obtained from structural magnetic resonance imaging (MRI) from individuals with mild dementia (n = 70) or mild cognitive impairment (MCI; n = 303) enrolled in the Alzheimer's Disease Neuroimaging Initiative.RESULTS: Ventricular volume and hippocampal volume showed the best precision in detecting change over time in both individuals with MCI and with dementia. Differences in clinical validity varied by group.DISCUSSION: The methodology presented provides a standardized framework for comparison of biomarkers across modalities and across different methods used to generate similar measures and will help in the search for the most promising biomarkers.Highlights: A framework for comparison of biomarkers on pre‐defined criteria is presented. Criteria for comparison include precision in capturing change and clinical validity. Ventricular volume has high precision in change for both dementia and mild cognitive impairment (MCI) trials. Imaging measures’ performance in clinical validity varies more for dementia than for MCI.Keywords
Funding Information
- National Institute on Aging (U19 AG024904)
This publication has 28 references indexed in Scilit:
- Tau accumulation and atrophy predict amyloid independent cognitive decline in agingAlzheimer's & Dementia, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patientsAlzheimer's & Dementia, 2022
- CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN frameworkNeurobiology of Aging, 2022
- Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population StudyAnnals of Neurology, 2020
- Comparing progression biomarkers in clinical trials of early Alzheimer’s diseaseAnnals of Clinical and Translational Neurology, 2020
- Defining imaging biomarker cut points for brain aging and Alzheimer's diseaseAlzheimer's & Dementia, 2016
- Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpointsStatistics in Medicine, 2014
- Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging InitiativeAlzheimer's & Dementia, 2010
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989